We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Epigenomics Gets FDA Response Letter for Epi proColon Test

Epigenomics Gets FDA Response Letter for Epi proColon Test

June 4, 2014

The FDA has asked German diagnostics maker Epigenomics to provide evidence that its Epi proColon colorectal cancer blood test not give people a false sense of well-being and cause them to forego colonoscopies or fecal immunochemical tests — the current gold standards for colon cancer detection.

In a response to the company’s premarket approval application, submitted early last year, the FDA said the studies performed so far establish the clinical performance characteristics of the test, but do not provide sufficient evidence to warrant approval of Epi proColon.

The agency wants to see that the test is not a substitution for traditional CRC screening, but instead helps to increase screenings, said Epigenomics CEO Thomas Taapken during a Tuesday conference call. The company’s original clinical studies were performed in patients who had agreed to a routine screening colonoscopy.

Epigenomics will meet with the FDA at the end of June to discuss next steps and how to best address the outstanding questions, Taapken said. The company met with the FDA’s Medical Device Advisory Committee on March 26, and while the committee said the test’s “benefits outweigh its risks,” a “small and doable” study is still needed for U.S. approval, he added.

The study will be similar to Epigenomics’ 2012 Berlin Adherence Study, in which 178 average aged patients were asked to participate in a CRC colonoscopy. Only 38 percent agreed, but 80 percent of those who refused agreed to take a FIT or Epi proColon blood test.

The FDA wants patients who test positive for CRC via FIT or blood-based testing to then have a colonoscopy, Taapken said. The agency also wants data on how many patients initially say yes to a colonoscopy and how many say yes later to confirm their status. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.

Medical Devices Regulatory Affairs Submissions and Approvals

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing